Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MD920
- Development stage
- Unknown
- Lead developer
- AusBio
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
MD920 is a topical small molecule investigational drug developed by Aus Bio for the treatment of chronic wounds, specifically hard-to-heal chronic venous leg ulcers. The active ingredient of MD920 is a 1:1 ratio of gibberellic acid and its salt (gibberellic acid and salt 1:1). Gibberellic acid is a naturally occurring plant growth regulator (phytohormone) that has been shown to stimulate cell migration, particularly of fibroblasts, and exhibit anti-inflammatory properties. MD920 was formulated as a topical agent applied to a non-adhesive wound dressing and evaluated in a Phase 2/3 clinical trial in Australia in combination with standard multilayer compression bandaging. However, the trial was stopped early, and the clinical development of MD920 has been discontinued.
- Other names
- gibberellic acid and salt 1:1
Beyond the preview
Go deeper on MD920.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MD920.